heart failure reaching class IV on the New York Heart Association classification; or acute terminal heart failure following a massive myocardial infarction.

CARMAT’s aim is to offer a reliable new treatment and innovative therapeutic solution to heart failure patients, who are not eligible for a transplant and who have exhausted every drug-related possibility. It was launched in 2008 and is based in Vélizy-villacoublay.